EUVIMEDEUVIMED entdecken
Open Access

Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes

Eugenio Cersosimo iD, Mariam Alatrach, Carolina Solis-Herrera iD, Gozde Baskoy, John Adams, Andrea Hansis-Diarte, Amalia Gastaldelli, Alberto Chavez, Curtis Triplitt, Ralph A DeFronzo

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgad438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Eugenio Cersosimo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, University Health System, San A…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Glycosuria. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH/NIDDK, AstraZeneca Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

This study addresses the development of a new glucoregulatory mechanism in type 2 diabetes (T2D) patients treated with SGLT-2 inhibitors, which is independent of glucose, insulin and glucagon. The data suggest the presence of a potential trigger factor (s) arising in the kidney that stimulates endogenous glucose production (EGP) during sustained glycosuria.

Objective

To investigate effects of SGLT-2 inhibitor therapy together with GLP-1 receptor agonist on EGP and glucose kinetics in patients with T2D. Our hypothesis was that increased EGP in response to SGLT2i-induced glycosuria persists for a long period and is not abolished by GLP-1 RA stimulation of insulin secretion and glucagon suppression.

Methods

Seventy-five patients received a 5-hour dual-tracer oral glucose tolerance test (OGTT) (intravenous 3-(3H)-glucose oral (1-14C)-glucose): (1) before/after 1 of dapagliflozin (DAPA); exenatide (EXE), or both, DAPA/EXE (acute study), and (2) after 1 and 4 months of therapy with each drug.

Results

In the acute study, during the OGTT plasma glucose (PG) elevation was lower in EXE (Δ = 42 ± 1 mg/dL) than DAPA (Δ = 72 ± 3), and lower in DAPA/EXE (Δ = 11 ± 3) than EXE and DAPA. EGP decrease was lower in DAPA (Δ = −0.65 ± 0.03 mg/kg/min) than EXE (Δ = −0.96 ± 0.07); in DAPA/EXE (Δ = −0.84 ± 0.05) it was lower than EXE, higher than DAPA. At 1 month, similar PG elevations (EXE, Δ = 26 ± 1 mg/dL; DAPA, Δ = 62 ± 2, DAPA/EXE, Δ = 27 ± 1) and EGP decreases (DAPA, Δ = −0.60 ± 0.05 mg/kg/min; EXE, Δ = −0.77 ± 0.04; DAPA/EXE, Δ = −0.72 ± 0.03) were observed. At 4 months, PG elevations (EXE, Δ = 55 ± 2 mg/dL; DAPA, Δ = 65 ± 6; DAPA/EXE, Δ = 46 ± 2) and lower EGP decrease in DAPA (Δ = −0.66 ± 0.04 mg/kg/min) vs EXE (Δ = −0.84 ± 0.05) were also comparable; in DAPA/EXE (Δ = −0.65 ± 0.03) it was equal to DAPA and lower than EXE. Changes in plasma insulin/glucagon could not explain higher EGP in DAPA/EXE vs EXE mg/kg/min.

Conclusion

Our findings provide strong evidence for the emergence of a new long-lasting, glucose-independent, insulin/glucagon-independent, glucoregulatory mechanism via which SGLT2i-induced glycosuria stimulates EGP in patients with T2D. SGLT2i plus GLP-1 receptor agonist combination therapy is accompanied by superior glycemic control vs monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsGlycosuriaHumansExenatideGlucagonHypoglycemic AgentsGlycemic ControlGlucagon-Like Peptide-1 Receptor AgonistsBlood GlucoseInsulinGlucoseBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

GLP-1 receptor agonistsSGLT-2 inhibitorsendogenous glucose productionglucose regulationkidneytype 2 diabetes

Substanzen

ExenatideGlucagonHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsBlood GlucoseInsulinGlucoseSodium-Glucose Transporter 2 InhibitorsdapagliflozinBenzhydryl Compounds

Autor:innen und Institutionen

  • Department of Medicine, Division of Diabetes, University of Texas Health Science Center and Texas Diabetes Institute, University Health System, San Antonio, TX 78229, USA.

ORCID-Profile: Eugenio Cersosimo, Carolina Solis-Herrera

Förderung

  • NIDDK NIH HHS
  • NIH/NIDDK
  • AstraZeneca Pharmaceuticals
  • NIH

Zitieren

APA

Cersosimo, E., Alatrach, M., Solis-Herrera, C., Baskoy, G., Adams, J., Hansis-Diarte, A., Gastaldelli, A., Chavez, A., Triplitt, C., & DeFronzo, R. A. (2023). Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad438

Vancouver

Cersosimo E, Alatrach M, Solis-Herrera C, Baskoy G, Adams J, Hansis-Diarte A, et al. Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad438

BibTeX
@article{Cersosimo2023,
  author = {Cersosimo, Eugenio and Alatrach, Mariam and Solis-Herrera, Carolina and Baskoy, Gozde and Adams, John and Hansis-Diarte, Andrea and Gastaldelli, Amalia and Chavez, Alberto and Triplitt, Curtis and DeFronzo, Ralph A},
  title = {Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgad438}
}
Kostenlos starten →